Epilepsy Market 2019 Industry Size, Key Highlights, Growth Analysis, Clinical Therapeutics, Competitive Share, Regional Scope and Forecast To 2023
The anti-epilepsy drugs market is likely to expand at a steady pace
across the globe. Market Research Future stated in its recently published
reports that the worldwide anti-epilepsy drugs market is growing and can be
estimated to gain momentum during 2017 to 2022. The market has been anticipated
to reflect a consistent upsurge by the conclusion of 2022, surpassing its
earlier growth records in terms of worth with a remarkable CAGR over the
forecast period.
Global Epilepsy Market Key Players
The global anti-epilepsy drugs market has been dominated by key players such as Johnson & Johnson, Pfizer, Inc., Abbott, UCB Pharma Ltd., GlaxoSmithKline plc, Sanofi, Novartis AG, Cephalon Inc., and Shire Pharmaceuticals Limited. These are some of the noteworthy players at the forefront of rivalry in the global anti-epilepsy drugs market which have been profiled in MRFR AnalysisBrowse complete The current research on epilepsy and epileptic meds on anti-epileptics
By condition, the ‘others’ segment accounted for 70.5% market share in 2017. It is touted to reach a worth close to USD 6,571.40 million by 2023. On the other hand, the drug resistant epilepsy segment is projected to reach a valuation of USD 2,937.80 million by the end of the forecast period. Emergence of rational polytherapy for treating the disorder with negligible side-effects is likely to accrue significant revenue for the epilepsy market.
By diagnosis & treatment, the treatment segment held 66.2% share
of the epilepsy market in 2017. The segment can exhibit 7.91% CAGR during the
forecast period due to availability of affordable drugs for treating partial
epileptic seizures. In addition, approval of effective drugs by regulatory
agencies can facilitate growth in the segment. It is expected to be worth USD
6,198.63 million by 2023. On the other hand, the diagnosis segment is predicted
to enjoy 8.76% CAGR over the assessment period. Utilization of various imaging
tests and blood tests for early discernment of the disorder is expected to
drive the segment growth exponentially. For instance, CT scans are used for
revealing abnormalities in the brain which can catch the probability of
epilepsy at an early stage.
Comments
Post a Comment